Avelumab/Axitinib versus Ipilimumab/Nivolumab: a Kent Oncology Centre Real-world Experience of First-line Combination Treatment for Metastatic Renal Cell Carcinoma. Issue 2 (February 2023)

Record Type:: Journal Article
Title:: Avelumab/Axitinib versus Ipilimumab/Nivolumab: a Kent Oncology Centre Real-world Experience of First-line Combination Treatment for Metastatic Renal Cell Carcinoma. Issue 2 (February 2023)
Main Title:: Avelumab/Axitinib versus Ipilimumab/Nivolumab: a Kent Oncology Centre Real-world Experience of First-line Combination Treatment for Metastatic Renal Cell Carcinoma
Authors:: Fenton, M.
Bianchini, D.
Brulinski, P.
Abstract:
Is Part Of:: Clinical oncology. Volume 35:Issue 2(2023)
Journal:: Clinical oncology
Issue:: Volume 35:Issue 2(2023)
Issue Display:: Volume 35, Issue 2 (2023)
Year:: 2023
Volume:: 35
Issue:: 2
Issue Sort Value:: 2023-0035-0002-0000
Page Start:: e237
Page End:
Publication Date:: 2023-02
Subjects:: Oncology -- Periodicals
Tumors -- Periodicals
Cancer -- Treatment -- Periodicals
Radiotherapy -- Periodicals
Neoplasms -- Periodicals
Cancer -- Radiotherapy
Cancer -- Treatment
Oncology
Medical radiology
Radiotherapy
Tumors
Electronic journals
Periodicals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09366555 ↗
http://www.elsevier.com/journal ↗
DOI:: 10.1016/j.clon.2022.11.027 ↗
Languages:: English
ISSNs:: 0936-6555
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3286.317000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 25128.xml